AOD-9604
HGH Fragment 177-191
AOD-9604 is a modified fragment of human growth hormone (hGH) corresponding to amino acids 177-191 of the hGH sequence. Unlike full hGH, AOD-9604 specifically targets fat metabolism without the side effects associated with full hGH, such as insulin resistance or cell proliferation. It stimulates lipolysis and inhibits lipogenesis, making it valuable for body composition research.
Key Benefits
Available Sizes
B2B Wholesale Only · For Research Use Only · COA Provided with Every Order
Product Description
AOD-9604 is a modified fragment of human growth hormone (hGH) corresponding to amino acids 177-191 of the hGH sequence. Unlike full hGH, AOD-9604 specifically targets fat metabolism without the side effects associated with full hGH, such as insulin resistance or cell proliferation. It stimulates lipolysis and inhibits lipogenesis, making it valuable for body composition research.
Amino Acid Sequence
Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-NH₂
Molecular Information
Request a Wholesale Quote
Fill out the form and our B2B team will respond within 24 hours with pricing, MOQ, and availability for AOD-9604.
Related Research
Peer-reviewed scientific literature on AOD-9604 from PubMed, NEJM, The Lancet, and other authoritative sources.
Research Use Only. The following citations are provided for informational purposes and represent independent scientific research. These studies do not constitute medical advice or claims about our products. All products are sold for research purposes only and are not intended for human use.
Metabolic Effects of AOD9604: A Modified Fragment of Human Growth Hormone
Heffernan M, Summers RJ, Thorburn A, et al.
Endocrinology, 142: 920–927 (2001)
AOD9604 significantly reduced body fat in obese animals through direct stimulation of lipolysis and inhibition of lipogenesis, with no effect on blood glucose levels or IGF-1 concentrations, demonstrating a clean metabolic profile.
Long-Term Treatment with AOD9604 Does Not Promote Insulin Resistance or Adverse Metabolic Effects
Ng FM, Sun J, Sharma L, et al.
Journal of Endocrinology, 164: R1–R6 (2000)
Unlike full-length hGH, AOD9604 did not induce insulin resistance, hyperglycemia, or elevated IGF-1 levels during long-term treatment, while still producing significant reductions in adipose tissue mass.
Citations sourced from PubMed / NCBI, New England Journal of Medicine, The Lancet, Nature, and other peer-reviewed publications. DOI links lead to original publisher pages.
Related Products
Semaglutide
GLP-1 receptor agonist for metabolic research and weight management applications.
Tirzepatide
Dual GIP/GLP-1 receptor agonist. Widely used in metabolic and weight management research.
Retatrutide
Triple-agonist candidate for advanced metabolic regulation and adiposity research.